System And Method For Providing A Personalized Tool For Estimating Glycated Hemoglobin

• US 20100145174A1
• Filed: 02/17/2009
• Published: 06/10/2010
• Est. Priority Date: 02/12/2008
• Status: Abandoned Application

• Current Assignee: Clifton A. Alferness, Gust H. Bardy
• Original Assignee: Clifton A. Alferness, Gust H. Bardy
• Inventors: Bardy, Gust H., Alferness, Clifton A.
• Application Number:
  US12/372,662
• Publication Number:
  US 20100145174A1
• Time in Patent Office: Days
• US Class Current: 600/365
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: G01N 33/723 Glycosylated haemoglobin
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 15/00 ICT specially adapted for medical reports, e.g. generation or transmission thereof
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 20/30 relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• CPC Class Codes: G16H 20/60 relating to nutrition control, e.g. diets
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

A system and method for providing a personalized tool for estimating glycated hemoglobin is provided. An electronically-stored history of empirically measured glucose levels for a patient is maintained over a set period of time in order of increasing age. A decay factor is applied to each of the measured glucose levels. The measured glucose levels are aggregated and scaled as decayed into an estimate of glycated hemoglobin for the time period. The glycated hemoglobin estimate is displayed to the patient.

Claims

1. A system for providing a personalized tool for estimating glycated hemoglobin, comprising:

a database configured to maintain an electronically-stored history of empirically measured glucose levels for a patient over a set period of time in order of increasing age; and

a prediction module, comprising;

a decay module configured to apply a decay factor to each of the measured glucose levels;

a scaling module configured to aggregate and scale the measured glucose levels as decayed into an estimate of glycated hemoglobin for the time period; and

a display module configured to display the glycated hemoglobin estimate to the patient.

2. A system according to claim 1, further comprising:

an estimation module, comprising;

an aggregation module configured to aggregate the measured glucose levels;

a scaling module configured to scale a summation of the measured glucose levels as an estimate of accuracy of the glycated hemoglobin estimate,

wherein the display module is further configured to display the estimate of accuracy to the patient.

3. A system according to claim 1, further comprising:

an interpolation module configured to interpolate estimated glucose levels at each of the regular intervals along the time period between each pair of the measured glucose levels in the history,

wherein the decay module is further configured to apply a decay factor to each of the estimated glucose levels, and the scaling module is further configured to aggregate and scale the estimated glucose levels as decayed with the measured glucose levels as decayed into the estimate of glycated hemoglobin for the time period.

4. A system according to claim 3, wherein each such estimated glucose level is established as one of a linear and an exponential interpolation of each such pair of measured glucose levels maintained immediately adjacent to each other in the history.

5. A system according to claim 1, further comprising:

an exponential decay function defined beginning at a most recent point in the time period, wherein the decay factor is chosen as a value of the exponential decay function corresponding to the regular interval for each of the measured glucose levels.

6. A system according to claim 1, wherein an exponential decay function is defined comprising fifty percent of the area of a curve projected over the first 30 days of the time period, wherein the time period comprises between 90 to 120 days.

7. A system according to claim 6, further comprising:

an exponential decay function ƒ

(x) expressed in accordance with;

ƒ

(x)=e^{31 λ}

where x is one such regular interval, and λ

comprises a decay constant between 40 percent and 60 percent.

8. A system according to claim 1, wherein the regular intervals comprise one of by-the-minute, by-the-hour, by-the-day, and by-the-week.

9. A system according to claim 1, wherein the glucose levels are obtained through at least one of blood glucose, interstitial, tissue, and cellular glucose measurement.

10. A method for providing a personalized tool for estimating glycated hemoglobin, comprising:

maintaining an electronically-stored history of empirically measured glucose levels for a patient over a set period of time in order of increasing age;

applying a decay factor to each of the measured glucose levels;

aggregating and scaling the measured glucose levels as decayed into an estimate of glycated hemoglobin for the time period; and

displaying the glycated hemoglobin estimate to the patient.

11. A method according to claim 10, further comprising:

aggregating the measured glucose levels;

scaling a summation of the measured glucose levels as an estimate of accuracy of the glycated hemoglobin estimate; and

displaying the estimate of accuracy to the patient.

12. A method according to claim 10, further comprising:

interpolating estimated glucose levels at each of the regular intervals along the time period between each pair of the measured glucose levels in the history;

applying a decay factor to each of the estimated glucose levels; and

aggregating and scaling the estimated glucose levels as decayed with the measured glucose levels as decayed into the estimate of glycated hemoglobin for the time period.

13. A method according to claim 12, further comprising:

establishing each such estimated glucose level as one of a linear and an exponential interpolation of each such pair of measured glucose levels maintained immediately adjacent to each other in the history.

14. A method according to claim 10, further comprising:

defining an exponential decay function beginning at a most recent point in the time period; and

choosing the decay factor as a value of the exponential decay function corresponding to the regular interval for each of the measured glucose levels.

15. A method according to claim 10, further comprising:

defining an exponential decay function comprising fifty percent of the area of a curve projected over the first 30 days of the time period, wherein the time period comprises between 100 to 120 days.

16. A method according to claim 15, further comprising:

expressing the exponential decay function ƒ

(x) in accordance with;

ƒ

(x)=e<sup>−

λ</sup>

where x is one such regular interval, and λ

comprises a decay constant between 40 percent and 60 percent.

17. A method according to claim 10, wherein the regular intervals comprise one of by-the-minute, by-the-hour, by-the-day, and by-the-week.

18. A method according to claim 10, wherein the glucose levels are obtained through at least one of blood glucose, interstitial, tissue, and cellular glucose measurement.

19. A system for creating a personalized tool for estimating a time course of glucose effect for a diabetic patient, comprising:

a database configured to maintain a patient history comprising a multiplicity of empirically measured glucose levels for a diabetic patient ordered by increasing age;

a prediction module comprising;

regular intervals defined within the patient history, wherein each of the measured glucose levels is assigned to the regular interval most closely corresponding to the age of the glucose level;

an exponential decay function projected over part of the patient history;

a decay module configured to adjust each of the measured glucose levels within the part of the patient history by the exponential decay function;

a scaling module configured to take a summation of the adjusted measured glucose levels and scaling the summation into an estimate of glycated hemoglobin; and

a display module configured to display the glycated hemoglobin estimate and the measured glucose levels comprised in the part of the patient history to the diabetic patient.

20. A system according to claim 19, further comprising:

an estimation module configured to take a summation of the measured glucose levels comprised in the part of the patient history, and to scale the summation as an estimate of accuracy of the glycated hemoglobin estimate, wherein the display module is further configured to display the estimate of accuracy to the diabetic patient.

21. A system according to claim 19, further comprising:

an interpolation module configured to create estimated glucose levels at each regular interval occurring between each pair of the measured glucose levels,

wherein the decay module is further configured to adjust each of the estimated glucose levels within the part of the patient history by the exponential decay function, and the estimated glucose levels are included in the summation.

22. A system according to claim 19, wherein the glucose levels are obtained through at least one of blood glucose, interstitial, tissue, and cellular glucose measurement.

23. A system according to claim 19, further comprising:

stored information comprising;

a substance and a quantity of the substance whose introduction triggers a physiological effect on the diabetic patient'"'"'s glucose; and

an analysis module configured to determine a time course and an amplitude of change for the physiological effect on expected glucose levels of the diabetic patient, wherein the display module is further configured to display the time course and the amplitude of change to the diabetic patient.

24. A system according to claim 23, wherein the stored information further comprises an insulin preparation as the substance and a predetermined bolus as the quantity of the substance, and an insulin sensitivity of the diabetic patient as an adjustment factor, further comprising:

an evaluation module configured to modify the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises mediating transport of glucose into cells in proportion to the insulin sensitivity.

25. A system according to claim 23, wherein the stored information further comprises one of an antidiabetic medication and an oral medication as the substance and a predetermined dosage as the quantity of the substance, and a physiological reaction to the medication as an adjustment factor, further comprising:

an evaluation module configured to modify the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises triggering a hematological interaction with glucose as the physiological reaction.

26. A system according to claim 23, wherein the stored information further comprises carbohydrates as the substance and a predetermined food item as the quantity of the substance, and a carbohydrate sensitivity as an adjustment factor, further comprising:

an evaluation module configured to modify the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises causing a rise in glucose in proportion to the carbohydrate sensitivity.

27. A method for creating a personalized tool for estimating a time course of glucose effect for a diabetic patient, comprising:

storing a patient history comprising a multiplicity of empirically measured glucose levels for a diabetic patient ordered by increasing age;

defining regular intervals within the patient history;

assigning each of the measured glucose levels to the regular interval most closely corresponding to the age of the glucose level;

projecting an exponential decay function over part of the patient history;

adjusting each of the measured glucose levels within the part of the patient history by the exponential decay function; and

taking a summation of the adjusted measured glucose levels and scaling the summation into an estimate of glycated hemoglobin; and

displaying the glycated hemoglobin estimate and the measured glucose levels comprised in the part of the patient history to the diabetic patient.

28. A method according to claim 27, further comprising:

taking a summation of the measured glucose levels comprised in the part of the patient history;

scaling the summation as an estimate of accuracy of the glycated hemoglobin estimate; and

displaying the estimate of accuracy to the diabetic patient.

29. A method according to claim 27, further comprising:

creating estimated glucose levels at each regular interval occurring between each pair of the measured glucose levels;

adjusting each of the estimated glucose levels within the part of the patient history by the exponential decay function; and

including the estimated glucose levels in the summation.

30. A method according to claim 27, wherein the glucose levels are obtained through at least one of blood glucose, interstitial, tissue, and cellular glucose measurement.

31. A method according to claim 27, further comprising:

selecting a substance and a quantity of the substance whose introduction triggers a physiological effect on the diabetic patient'"'"'s glucose;

determining a time course and an amplitude of change for the physiological effect on expected glucose levels of the diabetic patient; and

displaying the time course and the amplitude of change to the diabetic patient.

32. A method according to claim 31, further comprising:

specifying an insulin preparation as the substance and a predetermined bolus as the quantity of the substance;

specifying an insulin sensitivity of the diabetic patient as an adjustment S factor; and

modifying the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises mediating transport of glucose into cells in proportion to the insulin sensitivity.

33. A method according to claim 31, further comprising:

specifying one of an antidiabetic medication and, an oral medication as the substance and a predetermined dosage as the quantity of the substance;

specifying a physiological reaction to the medication as an adjustment factor; and

modifying the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises triggering a hematological interaction with glucose as the physiological reaction.

34. A method according to claim 31, further comprising:

specifying carbohydrates as the substance and a predetermined food item as the quantity of the substance;

specifying a carbohydrate sensitivity as an adjustment factor; and

modifying the time course and the amplitude of change by the adjustment factor, wherein the affect of the substance comprises causing a rise in glucose in proportion to the carbohydrate sensitivity.